• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Antiobesity Medications: Expert Discusses Older, Newer Therapies

News
Video

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

How do older antiobesity medications, such as bupropion/naltrexone, phentermine/topirimate, and orlistat differ from the more recently approved GLP-1RAs liraglutide and semaglutide 2.4 mg?

Was a question Patient Care Online asked medical weight management specialist Sandra Christensen, MSN, ARNP, in a recent interview on antiobesity medications.

In the video below, Ms Christensen gives a primer on common antiobesity medications and discusses the differences between older antiobesity medications and newer GLP-1RA therapies.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
© 2024 MJH Life Sciences

All rights reserved.